CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip
Identifying new and even more precise technologies for modifying and manipulating selectively specific genes has provided a powerful tool for characterizing gene functions in basic research and potential therapeutics for genome regulation. The rapid development of nuclease-based techniques such as C...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Materials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1996-1944/14/12/3164 |
| _version_ | 1797530858085679104 |
|---|---|
| author | Noshad Peyravian Maziar Malekzadeh Kebria Jafar Kiani Peiman Brouki Milan Masoud Mozafari |
| author_facet | Noshad Peyravian Maziar Malekzadeh Kebria Jafar Kiani Peiman Brouki Milan Masoud Mozafari |
| author_sort | Noshad Peyravian |
| collection | DOAJ |
| description | Identifying new and even more precise technologies for modifying and manipulating selectively specific genes has provided a powerful tool for characterizing gene functions in basic research and potential therapeutics for genome regulation. The rapid development of nuclease-based techniques such as CRISPR/Cas systems has revolutionized new genome engineering and medicine possibilities. Additionally, the appropriate delivery procedures regarding CRISPR/Cas systems are critical, and a large number of previous reviews have focused on the CRISPR/Cas9–12 and 13 delivery methods. Still, despite all efforts, the in vivo delivery of the CAS gene systems remains challenging. The transfection of CRISPR components can often be inefficient when applying conventional delivery tools including viral elements and chemical vectors because of the restricted packaging size and incompetency of some cell types. Therefore, physical methods such as microfluidic systems are more applicable for in vitro delivery. This review focuses on the recent advancements of microfluidic systems to deliver CRISPR/Cas systems in clinical and therapy investigations. |
| first_indexed | 2024-03-10T10:35:00Z |
| format | Article |
| id | doaj.art-3a2e8b9d5bd545c3819ae6a8f9026d3d |
| institution | Directory Open Access Journal |
| issn | 1996-1944 |
| language | English |
| last_indexed | 2024-03-10T10:35:00Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Materials |
| spelling | doaj.art-3a2e8b9d5bd545c3819ae6a8f9026d3d2023-11-21T23:20:11ZengMDPI AGMaterials1996-19442021-06-011412316410.3390/ma14123164CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation ChipNoshad Peyravian0Maziar Malekzadeh Kebria1Jafar Kiani2Peiman Brouki Milan3Masoud Mozafari4Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, IranCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, IranDepartment of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 1449614535, IranCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, IranDepartment of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 1449614535, IranIdentifying new and even more precise technologies for modifying and manipulating selectively specific genes has provided a powerful tool for characterizing gene functions in basic research and potential therapeutics for genome regulation. The rapid development of nuclease-based techniques such as CRISPR/Cas systems has revolutionized new genome engineering and medicine possibilities. Additionally, the appropriate delivery procedures regarding CRISPR/Cas systems are critical, and a large number of previous reviews have focused on the CRISPR/Cas9–12 and 13 delivery methods. Still, despite all efforts, the in vivo delivery of the CAS gene systems remains challenging. The transfection of CRISPR components can often be inefficient when applying conventional delivery tools including viral elements and chemical vectors because of the restricted packaging size and incompetency of some cell types. Therefore, physical methods such as microfluidic systems are more applicable for in vitro delivery. This review focuses on the recent advancements of microfluidic systems to deliver CRISPR/Cas systems in clinical and therapy investigations.https://www.mdpi.com/1996-1944/14/12/3164CRISPRmicrofluidicsgenomeCas9 proteintissue engineering |
| spellingShingle | Noshad Peyravian Maziar Malekzadeh Kebria Jafar Kiani Peiman Brouki Milan Masoud Mozafari CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip Materials CRISPR microfluidics genome Cas9 protein tissue engineering |
| title | CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip |
| title_full | CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip |
| title_fullStr | CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip |
| title_full_unstemmed | CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip |
| title_short | CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip |
| title_sort | crispr associated cas effectors delivery via microfluidic cell deformation chip |
| topic | CRISPR microfluidics genome Cas9 protein tissue engineering |
| url | https://www.mdpi.com/1996-1944/14/12/3164 |
| work_keys_str_mv | AT noshadpeyravian crisprassociatedcaseffectorsdeliveryviamicrofluidiccelldeformationchip AT maziarmalekzadehkebria crisprassociatedcaseffectorsdeliveryviamicrofluidiccelldeformationchip AT jafarkiani crisprassociatedcaseffectorsdeliveryviamicrofluidiccelldeformationchip AT peimanbroukimilan crisprassociatedcaseffectorsdeliveryviamicrofluidiccelldeformationchip AT masoudmozafari crisprassociatedcaseffectorsdeliveryviamicrofluidiccelldeformationchip |